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Purpose: The present study was designed to determine 
whether the combination of carboplatin (CBDCA) with 
paclitaxel (PTX) spared CBDCA-induced thrombocytopenia 
by increased plasma thrombopoietin (TPO) levels. 
Methods: Patients with non-small-cell and small-cell lung 
cancer were consecutively assigned to CBDCA with PTX 
regimen (CBDCA/PTX) and CBDCA with irinotecan (CPT-11) 
regimen (CBDCA/CPT-11), respectively. 
Results: Ten patients were entered into either CBDCA/PTX 
(n=5) or CBDCA/CPT-11 (n=5). CBDCA/PTX showed a lesser 
reduction of platelet counts than CBDCA/CPT-11 (p<0.05), 
although more severe neutropenia was observed in 
CBDCA/PTX (p<0.01). The plasma TPO levels were inversely 
correlated with circulating platelet counts in CBDCA/PTX 
and CBDCA/CPT-11. However, the increased rate of plasma 
TPO levels in CBDCA/PTX was not significantly different 
from that in CBDCA/CPT-11. 
Conclusions: These findings suggest that the increased 
plasma TPO levels in CBDCA/PTX result secondarily from 
thrombocytopenia, and that circulating TPO is probably not 
involved in the platelet-sparing effect of PTX. 
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Introduction
 The combination chemotherapy of carboplatin 
(CBDCA) with paclitaxel (PTX) is one of the common 
regimens for advanced non-small cell lung cancer." 
CBDCA is a platinum agent, and inhibits cell growth 
by forming intrastrand DNA cross-links." PTX is an
anti-microtubule agent, and disturbs tubulin 
depolymerization.3' The dose-limiting toxicity of CBDCA 
is thrombocytopenia, and that of PTX is neutropenia 
accompanied by moderate thrombocytopenia. The 
combination of CBDCA with other myelosuppressive 
drugs usually enhances the severity of thrombocytopenia. 
However, the combination with PTX is reported to 
rather decrease the degree of CBDCA-induced 
thrombocytopenia. 4 - 6' The precise mechanism of the 
platelet-sparing effect of PTX remains undetermined. 
 Thrombopoietin (TPO) is one of the main regulators 
of megakaryocytopoiesis, and TPO is constitutively 
produced in the liver and enters into the circulation.'-') 
The plasma TPO levels are inversely related to circu-
lating platelet counts in cancer patients receiving che-
motherapy, suggesting that circulating platelets regu-
late the plasma TPO levels.' 9) Recombinant human 
TPO increases the circulating platelet counts, and re-
duces the need for platelet transfusion in cancer pa-
tients with CBDCA-induced thrombocytopenia.'•'°' 
Thus, the present study was designed to determine 
whether the combination with PTX further increased 
the plasma TPO levels and spared CBDCA-induced 
thrombocytopenia. In order to distinguish PTX-induced 
TPO from TPO up-regulated by thrombocytopenia, we 
examined the relationship of plasma TPO levels and 
circulating platelet counts in lung cancer patients re-
ceiving CBDCA and PTX, compared to those receiving 
CBDCA and irinotecan (CPT-11). CPT-11 is a 
topoisomerase-I inhibitor, and the major toxicity also 
includes neutropenia accompanied by moderate 
thrombocytopenia.")
Patients and methods
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Patient selection 
 Patients with histologically or cytologically docu-
mented lung cancer were candidates for this study.
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Patients with non-small-cell lung cancer were consecu-
tively assigned to the combination therapy of CBDCA 
with PTX (CBDCA/PTX), and those with small-cell 
lung cancer to the combination therapy of CBDCA 
with CPT-11 (CBDCA/CPT-11). Due to the ethical diffi-
culties, patients could not be allocated to the treat-
ment with CBDCA alone or the combination with an-
other drug. Since our phase II study has recently 
revealed that CBDCA/CPT-11 is promising for the 
treatment of small-cell lung cancer,`' CBDCA/CPT-11 
was selected as the control. 
 Eligibility criteria were as follows: Stage IIIB or IV 
disease without the indication of radiation therapy; 
age below 75 years; performance status of 2 or better; 
no prior chemotherapy or radiation therapy within 4 
weeks; adequate hematopoietic function with neutrophil 
counts>2,000/,uL, platelet counts>100,000/,uL, and he-
moglobin levels>9.0g/dL; and normal hepatic and 
renal function. Specific exclusion criteria included 
bone marrow metastasis, uncontrolled brain metasta-
sis, and massive pleural or pericardial effusion. All 
participants gave their written informed consent prior 
to the study.
Treatment schedule 
 Since the degree of CBDCA-induced thrombocytopenia 
is related to the area under the concentration time 
curve (AUC) of plasma CBDCA, 9' the same target AUC 
of 5 mg • min/mL was selected in both the CBDCA/ 
PTX and CBDCA/CPT-11 regimens. The actual dose 
of CBDCA was determined by multiplying 5 mg-min/ 
mL by CBDCA clearance predicted by the Chatelut 
formula."' 
 In the CBDCA/PTX regimen, 210 mg/m2 of PTX 
was administered for 3 hours, followed by a 2-hour 
rest, and then CBDCA was given for 1 hour on day 1. 
Although the dose of PTX was 225 mg/m2 when com-
bined with CBDCA in the USA and European coun-
tries, the maximum dose of PTX approved by the 
Japanese Government was 210 mg/m2.!> Patients re-
ceived premedication with 20 mg of intravenous 
dexamethasone 14 and 6 hours before PTX infusion. 
Additional premedication included 50 mg of oral 
diphenhydramine and 50 mg of intravenous ranitidine 
before PTX infusion. Each treatment cycle was 4 
weeks. 
 In the CBDCA/CPT-11 regimen, CBDCA was admin-
istered on day 1, and 50 mg/m2 of CPT-11 on days 1, 
8 and 15. The dose of CPT-11 was determined based 
on our phase I study."' CPT-11 was infused for 90 
minutes, followed by a 2-hour rest, and then CBDCA 
was given for 1 hour on day 1. The administration of
CPT-11 on day 8 or 15 was canceled if leukocyte co 
unts<3,000/ 11L or platelet counts<50,000/ fiL were ob-
served, or if any grade of diarrhea or fever > 38°C de-
veloped. Each treatment cycle was 4 weeks. When the 
circulating neutrophil counts were less than 500 / ,uL, 
recombinant human granulocyte colony stimulating fac-
tor (rhG-CSF) was administered subcutaneously in both 
the CBDCA/PTX and CBDCA/CPT-11 regimens.
Sample collection 
 Blood samples for measuring the plasma TPO levels 
and platelet counts were collected in each EDTA-
containing tube on days 1, 4, 8, 15, and 22 in the first 
cycle of chemotherapy. For the plasma TPO levels, 
plasma was immediately separated by centrifugation 
at 1,500 rpm for 10 minutes, and frozen at - 20°C until 
use. The plasma TPO levels were measured by en-
zyme-linked immunosorbent assay.") Platelet counts, 
total leukocyte counts, and differential cell counts 
were determined with an automated hematology ana-
lyzer (NE-8000, Sysmex Corporation, Kobe, Japan).
Statistical analysis 
 The plasma TPO levels were log-transformed for 
normalization. The difference of neutrophil counts, 
platelet counts, and plasma TPO levels between the 
two groups was evaluated by the Student's t -test. The 
relationship of platelet counts and plasma TPO levels 
was evaluated by regression analysis. The difference 
of the regression lines between the two groups was 
determined by analysis of covariance. Two-tailed 
p<0.05 was considered significant. Data were analyzed 
with the StatView software program (version 5.0; SAS 
Institute Inc., Cary, NC).
Results
 Ten patients were entered into either CBDCA/PTX 
(n=5) or CBDCA/CPT-11 (n=5) (Table 1). All ten pa-
tients were assessable for plasma TPO levels and cir-
culating platelet counts. There was no difference of 
sex-, age-distribution, performance status, circulating 
neutrophil counts, and platelet counts before the treat-
ment. The CBDCA/CPT-11 group included more pa-
tients with stage IV disease because of small-cell lung 
cancer. 
 CBDCA/PTX showed lower nadir neutrophil counts 
than CBDCA/CPT-11 (Figure IA, p<0.01). Contrary to 
the myelosuppression, however, CBDCA/PTX showed 
a lesser reduction of platelet counts than CBDCA/
Takashi Kasai et al : Plasma Thrombopoietin Levels in Lung Cancer Patients Treated with Paclitaxel
Table 1. Patient characteristics
                    CBDCA/PTX CBDCA/CPT-11 
No. of patients 5 5 
Sex 
 male/female 5/0 4/1 
Median age (range) 61(49-70) 65(52-70) 
Performance status 
 1/2/3/4 4/1/0/0 3/2/0/0 
Stage 
 11113/IV 4/1 1/4 
Pretreatment counts 
 Neutrophil counts (/gL) 4,352 + 1,451 3,554 ± 1,390 
 Platelet counts (x103/gL) 289 ± 98 258 ± 94
and 8, the platelet counts were similarly decreased in 
both CBDCA/PTX and CBDCA/CPT-11 (Figure 3A). 
On day 15, the platelet counts remained constant in 
CBDCA/PTX, and were higher than in CBDCA /CPT-
11 (p<0.01). In contrast, the plasma TPO levels were 
increased after the chemotherapy, but the increase 
was not different between the two groups (Figure 3B).
CBDCA, carboplatin; PTX, paclitaxel; CPT-11, irinotecan
CPT-11 (Figure 1B, p<0.05). There was no documented 
infection or platelet transfusion in the two groups. 
 Serial changes in the neutrophil counts are shown 
in Figure 2. The neutrophil counts were decreased 
from day 4 in CBDCA/CPT-11, and were decreased 
from day 8 in CBDCA/PTX. The nadir of neutropenia 
occurred from day 19 to day 22 (median, day 21) in 
CBDCA/CPT-11, and that occurred from day 11 to 
day 15 (median, day 11) in CBDCA/PTX. Two of five 
patients were treated with G-CSF in CBDCA/CPT-11. 
In contrast, all of five patients were treated with G-
CSF in CBDCA/PTX. 
 Serial changes in the platelet counts and plasma 
TPO levels were further examined. Between days 1
Figure 2. Serial changes in the circulating neutrophil 
counts after the chemotherapy. The closed circles represent 
the data for the combination of carboplatin with paclitaxel, 
and the open circles for the combination of carboplatin with 




  (n = 5)
CBDCA/PTX 
  (n = 5)
CBDCA/CPT-11 
  (n = 5)
Figure 1. The nadir counts of circulating neutrophils (A) and platelets (B) after the chemotherapy. The closed bars represent 
the data for the combination of carboplatin with paclitaxel (CBDCA/PTX), and the open bars for the combination of 
carboplatin with irinotecan (CBDCA/CPT-11). The vertical lines showed a standard deviation. CBDCA/PTX showed more in-
tense neutropenia (p<0.05) but less severe thrombocytopenia (p<0.01), compared to CBDCA/CPT-11.
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Figure 3. Serial changes in the circulating platelet counts (A) and plasma thrombopoietin (TPO) levels (B) after the chemo-
therapy. The closed circles represent the data for the combination of carboplatin with paclitaxel, and the open circles for the 
combination of carboplatin with irinotecan. The vertical lines show a standard deviation.
 The relationship of platelet counts and plasma TPO 
levels is shown in Figure 4. The plasma TPO levels 
were inversely correlated with the circulating platelet 
counts in patients treated with CBDCA/PTX (r=-0.629, 
p<0.001) and those receiving CBDCA/CPT-11 (r=-0.714, 
p<0.001). There was no significant difference of the re-
gression lines between the two groups.
Discussion
Circulating platelet counts (x103/pL)
Figure 4. The relationship between circulating platelet 
counts and plasma thrombopoietin (TPO) levels. The closed 
circles and solid line represent the data and the regression 
line for the combination of carboplatin with paclitaxel. The 
open circles and broken line show the data and the regres-
sion line for the combination of carboplatin with irinotecan. 
The plasma TPO levels were inversely correlated with the 
circulating platelet counts in each treatment. There was no 
significant difference between the two regression lines.
 The present study demonstrated that the combina-
tion with PTX reduced the severity of CBDCA-induced 
thrombocytopenia, although this combination resulted 
in more intense neutropenia. Following CBDCA/PTX 
therapy, the plasma TPO levels were increased in-
versely proportional to the circulating platelet counts. 
As shown in Figure 3, however, the increased rate of 
plasma TPO levels was not different from that of CBDCA 
/CPT-11 therapy with more intense thrombocytopenia. 
This finding suggests that the increased plasma TPO 
results from the up-regulation response to 
thrombocytopenia, and that circulating TPO is proba-
bly not involved in the platelet-sparing effect of PTX. 
 Several studies have revealed that the combination 
with PTX provides a protective effect against CBDCA-
induced thrombocytopenia. 4 - n A mathematical model 
shows that patients receiving CBDCA/PTX experience
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less severe thrombocytopenia, compared to historical 
controls receiving CBDCA alone." In another study, 
thrombocytopenia was significantly less in patients 
treated with intraperitoneal CBDCA and intravenous 
PTX infusion, compared to those with intraperitoneal 
CBDCA alone." In these studies, PTX does not affect 
the pharmacokinetics of CBDCA. A possible explana-
tion for the platelet-sparing effect of PTX includes the 
induced production of hematopoietic factors and the 
enhanced survival of platelet precursors. 
 Gene-targeting studies have established that TPO 
and stem-cell factor play an important role in 
megakaryocyte production." Patients treated with 
CBDCA/PTX are reported to show an elevation of 
serum TPO levels but not stem-cell factor."' Our study 
suggests that the increase in plasma TPO levels is sec-
ondarily due to thrombocytopenia, and that circulat-
ing TPO is probably not involved in the platelet-
sparing effect of PTX. However, PTX is reported to 
induce the release of TPO from normal marrow-
stromal cells in vitro."' Although the majority of TPO 
is produced in the liver and enters into the circulation," 
our results cannot exclude the possible roles of local 
hematopoietic factors in the bone marrow 
microenviroment. 
 Recent studies have showed that megakaryocytic 
cells are resistant to the cytotoxicity of CBDCA/PTX 
in vitro."-"' The megakaryocytic progenitors derived 
from normal bone marrow are likely to be resistant to 
CBDCA/P11llV, compared to -the + . er yt viii v myeloid 
progenitors."' Furthermore, CBDCA and PTX show an 
antagonistic effect on survival in megakaryoblastic 
leukemia cells, and the intracellular CBDCA levels are 
not different in the presence or absence of PTX.'$' The 
platelet-sparing effect is probably mediated by alterna-
tive mechanisms rather than circulating TPO, and fur-
ther investigations are needed to clarify the 
cytoprotection of platelet progenitors.
Conclusion
 Our study demonstrated that PTX reduced the se-
verity of CBDCA-induced thrombocytopenia in con-
trast to CPT-11, and that the platelet-sparing effect 
did not result from the increased plasma TPO levels.
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